Aromatic fatty acids, of which phenylacetate (PA) is a prototype, constitute a new class of low toxicity drugs with demonstrated antitumor activity in experimental models and in humans. We and others have shown that PA inhibits the growth of human breast cancer cells. Our data indicates the ER+ cells are markedly more sensitive to PA than are ER- cells suggesting there is """"""""cross-talk"""""""" between the PA and estrogen signaling pathways. We have now confirmed this hypothesis by obtaining data showing that PA can inhibit gene transcription mediated by the """"""""classical"""""""" estrogen response element located in the vitellogenin gene promoter (EREv). The overall objective of this proposal is to delineate the precise mechanism(s) by which PA derivatives modulate estrogen-mediated gene regulation in human breast cancer cells.
Specific aim #1 is to determine the method by which PA and some of its more potent derivatives inhibit estrogen signaling through EREv. To do this, we will characterize the nuclear protein(s) that are induced by the PA compounds to bind EREv in breast cancer cells, and the gene and cell type specificity of these effects. Our preliminary studies have shown that these compounds also downregulate transcription of cyclin D1, an important estrogen-responsive gene that is overexpressed in roughly 40 percent of all breast tumors, but does not contain a canoncal ERE.
Specific aim #2 is to establish the mechanism of this activity. Using transient transfections of MCF-7 breast cancer calls with cyclin D1-promoter-luciferase constructs, the precise boundaries and critical nucleotide positions within the cyclin D1 promoter will be determined by delineating the effects of specific mutations on promoter function. Biochemical analysis using gel retardation and footprinting will be performed to correlate function of critical PA-responsive sequences with specific DNA-protein binding.
Specific aim #3 is to evaluate the therapeutic consequences of the PA blockage of estrogen responsive genes in an aromatase transgenic mouse model. Using these mice, we have already determined that aromatase/estrogen-induced preneoplastic/neoplastic changes following lactation can be completely abrogated by systemic administration of the PA derivative 4-chlorophenylacetate. Using a variety of treatment protocols, we will now assess the full potential of this and other PA compounds to act as chemoprotective agents against estrogen-induced carcinogenesis both without and with the addition of environmental carcinogens like DMBA. Taken together, the information gained from these studies will provide a basic framework for the rationale use of PA analogs or similar acting compounds in the clinic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA085589-01A1
Application #
6258514
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Arya, Suresh
Project Start
2001-03-02
Project End
2006-02-28
Budget Start
2001-03-02
Budget End
2002-02-28
Support Year
1
Fiscal Year
2001
Total Cost
$284,794
Indirect Cost
Name
Emory University
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Sidell, Neil; Kirma, Nameer; Morgan, Eddie T et al. (2007) Inhibition of estrogen-induced mammary tumor formation in MMTV-aromatase transgenic mice by 4-chlorophenylacetate. Cancer Lett 251:302-10
Liu, Jingbo; Li, Jing; Sidell, Neil (2007) Modulation by phenylacetate of early estrogen-mediated events in MCF-7 breast cancer cells. Cancer Chemother Pharmacol 59:217-25
Liu, Jingbo; Sidell, Neil (2005) Anti-estrogenic effects of conjugated linoleic acid through modulation of estrogen receptor phosphorylation. Breast Cancer Res Treat 94:161-9
Sidell, Neil; Tanmahasamut, Prasong; Ewing, Douglas E et al. (2005) Transcriptional inhibition of the estrogen response element by antiestrogenic piperidinediones correlates with intercalation into DNA measured by energy calculations. J Steroid Biochem Mol Biol 96:335-45
Tanmahasamut, Prasong; Sidell, Neil (2005) Up-regulation of gap junctional intercellular communication and connexin43 expression by retinoic acid in human endometrial stromal cells. J Clin Endocrinol Metab 90:4151-6
Li, Jing; Sidell, Neil (2005) Growth-related oncogene produced in human breast cancer cells and regulated by Syk protein-tyrosine kinase. Int J Cancer 117:14-20
Han, Shouwei; Sidell, Neil; Roman, Jesse (2005) Fibronectin stimulates human lung carcinoma cell proliferation by suppressing p21 gene expression via signals involving Erk and Rho kinase. Cancer Lett 219:71-81
Tanmahasamut, Prasong; Liu, Jingbo; Hendry, Lawrence B et al. (2004) Conjugated linoleic acid blocks estrogen signaling in human breast cancer cells. J Nutr 134:674-80
Han, Shouwei; Sidell, Neil; Fisher, Paul B et al. (2004) Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells. Clin Cancer Res 10:1911-9
Wanichkul, Thitikorn; Han, Shouwei; Huang, Ruo-Pan et al. (2003) Cytokine regulation by peroxisome proliferator-activated receptor gamma in human endometrial cells. Fertil Steril 79 Suppl 1:763-9

Showing the most recent 10 out of 13 publications